Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Deferoxamine Mesylate
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The trial will investigate the company’s Deferoxamine Intradermal Drug Patch (DIDP), for the topical treatment of Sickle Cell Leg Ulcers (SCUs) in support of its Orphan Drug Designation awarded in March of 2019.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 15, 2020
Lead Product(s) : Deferoxamine Mesylate
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable